Ehab L Atallah

Trials

Studies that name Ehab L Atallah as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:37 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT05554419 · Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)

  National Cancer Institute (NCI) · not yet recruiting · Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Arising From Previous Myeloproliferative Neoplasm · principal investigator
• Ph1
  NCT01887587 · Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia

  Ehab L Atallah · terminated · Relapsed or Refractory Acute Lymphoblastic Leukemia, Relapsed or Refractory Lymphoblastic Lymphoma, Mixed Phenotype Acute Leukemia · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 11:37 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

• Stopping Tyrosine Kinase Inhibitors in CML Patients (Stop-TKIs)
  R01CA184798 · NCI · MEDICAL COLLEGE OF WISCONSIN · fiscal years 2014 to 2019 · $361,156 awarded in 2019
  Same name and institution; not confirmed by an ID

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• ECOG-ACRIN Network Group Operations Center
  U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2014 to 2026
  Named on NCT05554419